Evidence map›Paper›PMID 35962006›Full record

ArticleScientific reports2022

BDNF, proBDNF and IGF-1 serum levels in naïve and medicated subjects with autism.

Maria de Los Angeles Robinson-Agramonte, Bernadeta Michalski, Belkis Vidal-Martinez, Leyanis Ramos Hernández, Mabel Whilby Santiesteban, Margaret Fahnestock

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. The Ambiguous Role of Growth Factors in Autism: What Do We Really Know?International journal of molecular sciences · 2025
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Maria de Los Angeles Robinson-AgramonteNeuroimmunology Department, International Center for Neurological Restoration, Havana, Cuba.
Bernadeta MichalskiDepartment of Psychiatry and Behavioural Neurosciences, McMaster University, 1280 Main St. West, Hamilton, ON, L8S 4K1, Canada.
Belkis Vidal-MartinezChildren's Hospital Borrás-Marfán, Havana, Cuba.
Leyanis Ramos HernándezPsychiatry Department, Children's Hospital Las Católicas, Havana, Cuba.
Mabel Whilby SantiestebanPsychiatry Department, Children's Hospital Las Católicas, Havana, Cuba.
Margaret FahnestockDepartment of Psychiatry and Behavioural Neurosciences, McMaster University, 1280 Main St. West, Hamilton, ON, L8S 4K1, Canada. fahnest@mcmaster.ca.
McMaster University · CAInternational Center of Neurologic Restoration · CU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain-derived neurotrophic factor (BDNF) and insulin-like growth factor 1 (IGF-1) promote the development and maintenance of neural circuits. Alterations in these factors might contribute to autism spectrum disorder (ASD). We asked whether serum BDNF, proBDNF, and IGF-1 levels are altered in an ASD population compared to controls. We measured serum BDNF, proBDNF, and IGF-1 immunoreactive protein in boys and girls aged 5-15 years old with mild to moderate ASD and non-autistic controls by ELISA. IGF-1 was increased in ASD serum compared to controls and was correlated with age and with CARS scores. Serum BDNF levels did not differ between groups, however, proBDNF serum levels were decreased in subjects with ASD compared to non-autistic controls. Medicated, but not unmedicated, ASD subjects exhibited lower serum proBDNF levels compared to controls, while neither IGF-1 nor BDNF levels differed between treatment groups. These data support the involvement of proBDNF and IGF-1 in the pathogenesis and treatment of autism.

Indexed as

Autism Spectrum DisorderAutistic DisorderAdolescentBrain-Derived Neurotrophic FactorChildChild, PreschoolEnzyme-Linked Immunosorbent AssayFemaleHumansInsulin-Like Growth Factor IMaleBDNF protein, humanBrain-Derived Neurotrophic FactorIGF1 protein, humanInsulin-Like Growth Factor I

Identifiers

PMID35962006
PMCPMC9374711
OpenAlexW4290861146

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.